NO20026123D0 - Farmasöytiske sammensetninger - Google Patents

Farmasöytiske sammensetninger

Info

Publication number
NO20026123D0
NO20026123D0 NO20026123A NO20026123A NO20026123D0 NO 20026123 D0 NO20026123 D0 NO 20026123D0 NO 20026123 A NO20026123 A NO 20026123A NO 20026123 A NO20026123 A NO 20026123A NO 20026123 D0 NO20026123 D0 NO 20026123D0
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
valsartan
compositions
bioavailable
hydrate
Prior art date
Application number
NO20026123A
Other languages
English (en)
Other versions
NO20026123L (no
Inventor
Sabina Maria Ganter
Robert Frank Wagner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20026123D0 publication Critical patent/NO20026123D0/no
Publication of NO20026123L publication Critical patent/NO20026123L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20026123A 2000-06-22 2002-12-19 Farmasöytiske sammensetninger NO20026123L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Publications (2)

Publication Number Publication Date
NO20026123D0 true NO20026123D0 (no) 2002-12-19
NO20026123L NO20026123L (no) 2003-02-18

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026123A NO20026123L (no) 2000-06-22 2002-12-19 Farmasöytiske sammensetninger

Country Status (21)

Country Link
EP (2) EP1296677A2 (no)
JP (3) JP2003535895A (no)
KR (2) KR100659644B1 (no)
CN (2) CN100450478C (no)
AU (2) AU8576801A (no)
BR (1) BR0111868A (no)
CA (1) CA2411882C (no)
CZ (1) CZ20024180A3 (no)
EC (1) ECSP024389A (no)
HK (2) HK1052868A1 (no)
HU (1) HUP0301390A3 (no)
IL (2) IL153428A0 (no)
MX (1) MXPA02012683A (no)
NO (1) NO20026123L (no)
NZ (2) NZ540748A (no)
PL (1) PL358290A1 (no)
RU (1) RU2333757C2 (no)
SG (1) SG162605A1 (no)
SK (1) SK18062002A3 (no)
WO (1) WO2001097805A2 (no)
ZA (1) ZA200210359B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ293257B6 (cs) * 1998-12-23 2004-03-17 Novartis Ag Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě
BRPI0306907B8 (pt) * 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
SI2033629T1 (sl) 2004-12-24 2013-01-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Trden farmacevtski sestavek, ki obsega valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
RU2487710C2 (ru) 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
JPH09510225A (ja) * 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト バルサルタンを用いる糖尿病性ネフロパシーの治療
BR9611007A (pt) * 1995-10-06 1999-07-13 Novartis Ag Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos
DE69718146T2 (de) * 1996-02-29 2003-10-02 Novartis Ag At1 rezeptor antagonist zur anregung von apoptosis
EP0904060B1 (en) * 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
CZ293257B6 (cs) * 1998-12-23 2004-03-17 Novartis Ag Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě
PL365696A1 (en) * 2000-04-12 2005-01-10 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
MXPA02012683A (es) 2003-04-25
KR100659644B1 (ko) 2006-12-21
ECSP024389A (es) 2003-02-06
IL153428A (en) 2013-12-31
KR100525341B1 (ko) 2005-11-02
ZA200210359B (en) 2003-11-13
SK18062002A3 (sk) 2003-07-01
RU2333757C2 (ru) 2008-09-20
EP2072049A2 (en) 2009-06-24
CN1437469A (zh) 2003-08-20
AU8576801A (en) 2002-01-02
BR0111868A (pt) 2003-07-01
JP2003535895A (ja) 2003-12-02
KR20050085978A (ko) 2005-08-29
CN1221256C (zh) 2005-10-05
WO2001097805A2 (en) 2001-12-27
CA2411882C (en) 2011-09-06
NZ540748A (en) 2007-04-27
PL358290A1 (en) 2004-08-09
CA2411882A1 (en) 2001-12-27
HUP0301390A3 (en) 2005-04-28
HK1083452A1 (en) 2006-07-07
IL153428A0 (en) 2003-07-06
JP2012211200A (ja) 2012-11-01
WO2001097805A3 (en) 2002-08-29
KR20030019450A (ko) 2003-03-06
CN1679551A (zh) 2005-10-12
HUP0301390A2 (hu) 2003-11-28
HK1052868A1 (zh) 2003-10-03
CZ20024180A3 (cs) 2003-04-16
NZ522953A (en) 2005-10-28
NO20026123L (no) 2003-02-18
JP2007091758A (ja) 2007-04-12
AU2001285768B2 (en) 2005-03-10
SG162605A1 (en) 2010-07-29
EP1296677A2 (en) 2003-04-02
CN100450478C (zh) 2009-01-14
EP2072049A3 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
HK1083452A1 (en) Pharmaceutical compositions
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
MXPA03006476A (es) Composiciones farmaceuticas, formas de dosificacion y metodos para administracion oral de epotilonas.
TWI315204B (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
CA2427815A1 (en) Controlled release hydrocodone formulations
EP1797878A3 (en) Benzothiazole derivatives
HUP0203176A2 (hu) Szimetikont tartalmazó orális, szilárd adagolási forma
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
HK1076605A1 (en) Formulations
MA27107A1 (fr) Formulations aerosoles pour l'administration pulmonaire de medicaments visant a produire un effet systemique.
DE69413237D1 (en) Plättchenaggregationsinhibitoren
EA200301223A1 (ru) Лекарственные формы окскарбазепина
DE69530123D1 (en) Plättchenaggregationsinhibitoren
IL161991A0 (en) Oral dosage form of a sulfonamide prodrug such as parecoxib
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
HUP0400495A2 (hu) Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
BR0213463A (pt) Composições farmacêuticas contendo macrólidos
HUP0300032A3 (en) Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition
NO20011576D0 (no) Farmasöytiske blandinger basert på <alfa>-cyklodekstrin for oral administrasjon av LH-RH analoger
ID28649A (id) Komposisi dosis oral pelepasan yang diperpanjang